<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568174</url>
  </required_header>
  <id_info>
    <org_study_id>PN-1007-001</org_study_id>
    <nct_id>NCT04568174</nct_id>
  </id_info>
  <brief_title>First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy</brief_title>
  <official_title>First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PPSGG (PN-1007) in Anti-MAG Neuropathy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Polyneuron Pharmaceuticals AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Polyneuron Pharmaceuticals AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the new drug called PPSGG (PN-1007) will be tested. Preliminary studies&#xD;
      conducted in animals suggest PPSGG (PN-1007) might be a good treatment for reducing levels of&#xD;
      anti-MAG antibodies in patients with anti-MAG neuropathy.&#xD;
&#xD;
      This is the first research of PPSGG (PN-1007) in people and its main purpose is to test its&#xD;
      safety and acceptability in patients. In this study it will be examined how the drug is&#xD;
      changed by and removed from the body and checked for signs that the drug may be truly&#xD;
      effective against anti-MAG neuropathy. PPSGG (PN-1007) will be tested at several different&#xD;
      doses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PPSGG (PN-1007) is intended to bind anti-MAG IgM autoantibodies, the underlying cause of&#xD;
      anti-MAG neuropathy, in a highly selective manner, resulting in their neutralization and&#xD;
      removal from the circulation. This allows specific targeting of anti-MAG IgM in the&#xD;
      circulation and circumvents unspecific immunosuppression associated with current treatment&#xD;
      strategies.&#xD;
&#xD;
      This is a Phase I/IIa, First in Human (FiH), multicenter, single and multiple ascending dose&#xD;
      escalation trial of PPSGG (PN-1007), an antibody scavenger of pathogenic anti-MAG&#xD;
      immunoglobulin M (IgM) autoantibodies for treatment of anti-MAG neuropathy. The aim of the&#xD;
      study is to assess the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD),&#xD;
      and preliminary efficacy of PPSGG (PN-1007) in a SAD and a MAD phase in an adaptive trial in&#xD;
      anti-MAG neuropathy patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Data don't support further development&#xD;
  </why_stopped>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Actual">September 23, 2021</completion_date>
  <primary_completion_date type="Actual">September 23, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single Group in SAD and parallel in MAD</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The SAD phase is open label and MAD is randomized, dose escalation, double blind (patient and investigator blinded), placebo-controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>1 month</time_frame>
    <description>All AEs will be recorded, whether considered minor or serious, drug-related or not</description>
  </primary_outcome>
  <primary_outcome>
    <measure>anti-drug-antibodies ADA</measure>
    <time_frame>1 month in SAD</time_frame>
    <description>Potential ADAs (immunogenicity) resulting from exposure of patients to PPSGG (PN-1007) will be measured by ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Day 1 to Day 42</time_frame>
    <description>Time of peak concentration of PPSGG (PN-1007)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Day 1 to Day 42</time_frame>
    <description>Maximum Plasma Concentration of PPSGG (PN-1007)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>Day 1 to Day 42</time_frame>
    <description>Area under the plasma concentration versus time curve from zero to infinity of PPSGG (PN-1007)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>Day 1 to Day 42</time_frame>
    <description>Terminal half life of PPSGG (PN-1007)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic</measure>
    <time_frame>up to Day 28</time_frame>
    <description>Change in anti-MAG Buhlmann titer from baseline measured by ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ONLS</measure>
    <time_frame>up to Day 150 in MAD</time_frame>
    <description>Overall Neuropathy Limitations Scale measures limitations in the everyday activities of the upper and lower limbs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Anti-MAG Neuropathy</condition>
  <arm_group>
    <arm_group_label>PPSGG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sterile liquid, one 1-hour infusion in SAD and multiple infusions in MAD. In SAD multiple cohorts being tested. Dosage and regime in MAD to be defined based on SAD outcome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PPSGG</intervention_name>
    <description>an antibody scavenger of pathogenic anti-MAG immunoglobulin M (IgM) autoantibodies</description>
    <arm_group_label>PPSGG</arm_group_label>
    <other_name>PN-1007</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A standard PBS solution, pH 7.4, composed of disodium hydrogen phosphate dodecahydrate, potassium dihydrogen phosphate, sodium chloride, and water for injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of monoclonal IgM associated with MGUS with&#xD;
             anti-MAG activity (titer of &gt; 10'000 BTU) and demyelinating neuropathy defined by&#xD;
             electrophysiological criteria according to EFNS/PNS PDN guideline, 2010.&#xD;
&#xD;
          -  Clear clinical signs of disability&#xD;
&#xD;
          -  Adequate hepatic and renal function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with total serum IgM levels &gt;30 g.&#xD;
&#xD;
          -  Hematological malignancy, prior malignancy of any organ system (except BCC)&#xD;
&#xD;
          -  Prior immunosuppression: No IVIG in previous 3 months, no previous cyclophosphamide or&#xD;
             biologicals in prior 6 months.&#xD;
&#xD;
          -  Other neurological, neuromuscular, rheumatologic or orthopedic condition with&#xD;
             significant impact on the capabilities of walk preventing evaluation of neurological&#xD;
             scores&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hedvika Lazar</last_name>
    <role>Study Chair</role>
    <affiliation>Polyneuron Pharmaceuticals AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Neurologie Centre de Référence Neuropathies Périphériques Rares, CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87 042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Referral centre for neuromuscular diseases and ALS, hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Neurologie Pôle Neurosciences Centre de Référence des Neuropathies Amyloïdes Familiales et autres Neuropathies Périphériques Rares Centre Hospitalier Universitaire de Bicêtre</name>
      <address>
        <city>Paris</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht Cancer Center</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National hospital for neurology and neurosurgery, Queen London</name>
      <address>
        <city>London</city>
        <zip>WC1N 3bg</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2020</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

